Inhibit globally, act locally: CDK7 inhibitors in cancer therapy

Kaixiang Cao; Ali Shilatifard

doi:10.1016/j.ccr.2014.07.020

Inhibit globally, act locally: CDK7 inhibitors in cancer therapy

Cancer Cell. 2014 Aug 11;26(2):158-9. doi: 10.1016/j.ccr.2014.07.020.

Authors

Kaixiang Cao¹, Ali Shilatifard²

Affiliations

¹ Stowers Institute for Medical Research, 1000 East 50(th) Street, Kansas City, MO 64110, USA.
² Stowers Institute for Medical Research, 1000 East 50(th) Street, Kansas City, MO 64110, USA. Electronic address: ash@stowers.org.

PMID: 25117707
DOI: 10.1016/j.ccr.2014.07.020

Abstract

Cyclin-dependent kinases (CDKs) are involved in temporal control of the cell cycle and transcription and play central roles in cancer development and metastasis. Recently, Kwiatkowski and colleagues identified a novel CDK7-specific inhibitor, THZ1, that hinders proliferation in cancer cell lines and dampens global transcription in T cell leukemia.

Publication types

Comment

MeSH terms

Enzyme Inhibitors / pharmacology*
Gene Expression Regulation, Neoplastic / drug effects*
Humans
Phenylenediamines / pharmacology*
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / enzymology*
Pyrimidines / pharmacology*

Substances

Enzyme Inhibitors
Phenylenediamines
Pyrimidines